MANGOCEUTICALS, INC. Enters Material Definitive Agreement
Ticker: MGRX · Form: 8-K · Filed: Dec 10, 2025 · CIK: 1938046
| Field | Detail |
|---|---|
| Company | Mangoceuticals, INC. (MGRX) |
| Form Type | 8-K |
| Filed Date | Dec 10, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $75,000, $75,000, b |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation
TL;DR
MANGOCEUTICALS, INC. signed a big deal, creating new financial obligations.
AI Summary
On December 4, 2025, MANGOCEUTICALS, INC. entered into a material definitive agreement. This agreement also created a direct financial obligation or an obligation under an off-balance sheet arrangement for the registrant. The filing includes financial statements and exhibits related to this event.
Why It Matters
This filing indicates a significant new contractual commitment for MANGOCEUTICALS, INC., which could impact its financial obligations and future operations.
Risk Assessment
Risk Level: medium — Entering into material definitive agreements and creating new financial obligations can introduce financial and operational risks that are not yet fully understood.
Key Players & Entities
- MANGOCEUTICALS, INC. (company) — Registrant
- December 4, 2025 (date) — Date of Earliest Event Reported
- Texas (location) — State of Incorporation
- Dallas (location) — Principal Executive Offices City
- 75248 (postal_code) — Principal Executive Offices Zip Code
FAQ
What type of material definitive agreement did MANGOCEUTICALS, INC. enter into?
The filing does not specify the exact nature of the material definitive agreement, only that one was entered into on December 4, 2025.
What are the specific financial obligations created by this agreement?
The filing states that a direct financial obligation or an obligation under an off-balance sheet arrangement was created, but the specific details and amounts are not provided in this summary.
When was this agreement reported?
The earliest event reported in this filing occurred on December 4, 2025, and the filing was made as of December 10, 2025.
Where is MANGOCEUTICALS, INC. headquartered?
MANGOCEUTICALS, INC.'s principal executive offices are located at 17130 N. Dallas Parkway, Suite 240, Dallas, Texas, 75248.
What is the SEC file number for MANGOCEUTICALS, INC.?
The SEC file number for MANGOCEUTICALS, INC. is 001-41615.
Filing Stats: 925 words · 4 min read · ~3 pages · Grade level 13 · Accepted 2025-12-10 06:40:28
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share MGRX The Nasdaq Stock Mar
- $75,000 — Company ", " we " and " us "), borrowed $75,000 from The Tiger Cub Trust, which trust i
- $75,000, b — mber 4, 2025 in the principal amount of $75,000, between Mangoceuticals, Inc., borrower an
Filing Documents
- form8-k.htm (8-K) — 48KB
- ex10-1.htm (EX-10.1) — 94KB
- 0001493152-25-027009.txt ( ) — 324KB
- mgrx-20251204.xsd (EX-101.SCH) — 3KB
- mgrx-20251204_lab.xml (EX-101.LAB) — 33KB
- mgrx-20251204_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MANGOCEUTICALS, INC. Date: December 10, 2025 By: /s/ Jacob D. Cohen Jacob D. Cohen Chief Executive Officer